These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8847521)

  • 1. Expression of the herpes simplex virus type 1 glycoprotein E in human cells and in Escherichia coli: protection studies against lethal viral infection in mice.
    Miriagou V; Argnani R; Kakkanas A; Georgopoulou U; Manservigi R; Mavromara P
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():3137-43. PubMed ID: 8847521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL
    Virology; 1992 Jun; 188(2):469-76. PubMed ID: 1585630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge.
    Ghiasi H; Cai S; Slanina S; Nesburn AB; Wechsler SL
    Antiviral Res; 1995 Oct; 28(2):147-57. PubMed ID: 8585768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.
    Ghiasi H; Nesburn AB; Wechsler SL
    Vaccine; 1996 Feb; 14(2):107-12. PubMed ID: 8852405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
    Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL
    J Virol; 1994 Apr; 68(4):2118-26. PubMed ID: 8138996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced protection against HSV lethal challenges in mice by immunization with a combined HSV-1 glycoprotein B:H:L gene DNAs.
    Cha SC; Kim YS; Cho JK; Cho J; Kim SY; Kang H; Cho MH; Lee HH
    Virus Res; 2002 Jun; 86(1-2):21-31. PubMed ID: 12076826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.
    Lin XH; Ali MA; Openshaw H; Cantin EM
    Arch Virol; 1996; 141(6):1153-65. PubMed ID: 8712932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
    Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
    J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.
    McDermott MR; Graham FL; Hanke T; Johnson DC
    Virology; 1989 Mar; 169(1):244-7. PubMed ID: 2538036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
    Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L.
    Ghiasi H; Kaiwar R; Slanina S; Nesburn AB; Wechsler SL
    Arch Virol; 1994; 138(3-4):199-212. PubMed ID: 7998829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escherichia coli expressed herpes simplex virus gG1 and gG2 proteins in ELISA and immunoblotting assays.
    Kakkanas A; Papadogeorgaki H; Manservigi R; Miriagou V; Georgopoulou U; Mavromara P
    Intervirology; 1995; 38(6):346-51. PubMed ID: 8880385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.
    Chabalgoity JA; Khan CM; Nash AA; Hormaeche CE
    Mol Microbiol; 1996 Feb; 19(4):791-801. PubMed ID: 8820649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain.
    Koshizuka T; Ishioka K; Kobayashi T; Ikuta K; Suzutani T
    Fukushima J Med Sci; 2016 Jun; 62(1):36-42. PubMed ID: 26983589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.